INSTI(TM) a 60 Second HIV Testing Kit is Now Available to the European Community

Richmond, Canada (ots/PRNewswire) - bioLytical(TM) Laboratories
announced today, that their INSTI(TM) kit, a rapid HIV antibody test
developed by the company, received CE Mark approval in their European
Community.

"We are delighted to have received CE Mark approval for INSTI,"
says Robert Mackie, President and CEO. "To have CE Mark approval will
now allow us to enter the European market and target 28 different
countries."

INSTI is the only test approved by Health Canada for Point of Care
testing and is one of four tests approved in the European Union. With
the strictest accreditation behind the INSTI kit, these milestones
are a true verification of INSTI's quality and accuracy.

The CE mark is a mandatory European marking for certain product
groups to indicate conformity with the essential health and safety
requirements set out in European Directives. The letters 'CE' are an
abbreviation of Conformité Européenne, French for European
conformity.

INSTI(TM) is a highly effective and reliable rapid HIV test that
detects the presence of antibodies to HIV in whole blood, serum or
plasma in 60 seconds. It has a 99.96% accuracy rate, as demonstrated
in extensive clinical trials carried out in multiple centres across
Canada. To further ensure INSTI(TM) maintains its high quality, it is
manufactured in Canada under strict controls in a state-of-the-art
ISO accredited facility. INSTI has gone through extensive clinical
trials and is the only HIV kit approved by Health Canada for Point of
care testing. They are also registered in Uganda, Kenya, and Vietnam.

bioLytical(TM) Laboratories (Inc.) is a leading developer and
manufacturer of diagnostic tests for global health care markets. The
company produces the highly accurate and reliable INSTI(TM) kit; the
only rapid HIV test kit approved by Health Canada for use in a point
of care setting, such as a doctor's office or hospital.
bioLytical(TM) is a privately owned company with headquarters and
state of the art manufacturing facility located in Richmond, British
Columbia with an office in United Kingdom and Uganda, Africa. For
more information about bioLytical and INSTI(TM), please visit
www.biolytical.com.

ots Originaltext: bioLytical(TM) Laboratories (Inc.)
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Media Contact: Debbie Collins,
bioLytical(TM) Laboratories, Telephone: +1-604-204-6784 ext. 236,
Cell: +1-604-716-7934, Email: dcollins@biolytical.com